Dergiler / Turkish Journal of Medical Sciences / 2016 / Cilt: 46 - Sayı: 6

Do anxiety and depression statuses differ in different polycystic ovary syndrome phenotypes?

Sayfa
1846–1853
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Thus, psychiatric evaluations appear necessary for PCOS patients in order to diagnose and treat clinical depression and anxiety

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: To evaluate psychological parameters and health quality profiles in women with reproductive polycystic ovary syndrome (PCOS) phenotypes and age matched controls.
📊
Temel Bulgular & Veri:Materials and methods: The study groups included 101 women with PCOS (54 with the National Institutes of Health [NIH] phenotype and 47 with the non-NIH phenotype) and 49 healthy female controls.
💡
Sonuç & Katkı:Thus, psychiatric evaluations appear necessary for PCOS patients in order to diagnose and treat clinical depression and anxiety
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: To evaluate psychological parameters and health quality profiles in women with reproductive polycystic ovary syndrome (PCOS) phenotypes and age matched controls. Materials and methods: The study groups included 101 women with PCOS (54 with the National Institutes of Health [NIH] phenotype and 47 with the non-NIH phenotype) and 49 healthy female controls. The participants completed anxiety and depression scales and four quality of life domains. Results: We identified the women with PCOS as having a 3.39 times increased risk for depression (subscale ≥ 7) and a 3.64 times increased risk for anxiety (subscale ≥ 10) compared to the controls. Both NIH and non-NIH phenotypes showed similar rates of depression (46.3% vs. 46.8%, respectively; P = 0.57) and anxiety (31.5% vs. 36.2%, respectively; P = 0.47). Regarding the quality of life scale, the women with NIH PCOS had significantly lower mental health scores compared to those with non-NIH PCOS (P = 0.03). Furthermore, while mental health scores were similar in the women with PCOS and the controls, physical health scores were significantly lower in the women with PCOS (P = 0.007). Conclusion: Nearly half of the women with PCOS had higher depression scores and one third had higher anxiety scores. Thus, psychiatric evaluations appear necessary for PCOS patients in order to diagnose and treat clinical depression and anxiety

🔖

Bu Makaleye Atıf Yap

MOLLAMAHMUTOĞLU, L., ÖZELÇİ, R., AKPINAR, F., KOTAN, Z., CİRİK, D. A., AKSAKAL, S., DİLBAZ, B. (2022). Do anxiety and depression statuses differ in different polycystic ovary syndrome phenotypes?. Turkish Journal of Medical Sciences, Cilt: 46 - Sayı: 6, 1846–1853. https://ajindex.com/articles/610792

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group, Consensus on women’s health aspects of polycystic ovary syndrome (PCOS). Hum Reprod 2012; 27: 14-24
  2. Dokras A, Clifton S, Futterweit W, Wild R. Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis. Obstet Gynecol 2011; 117: 145-152
  3. Dokras A. Mood and anxiety disorder in women with PCOS. Steroids 2012; 77: 338-341
  4. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome; toward a rational approach. In: Dunaif A, Givens JR, Haseltine FP, editors. Polycystic Ovary Syndrome. Boston, MA, USA: Blackwell Scientific 1992; pp. 377-384
  5. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47
  6. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25: 544-551
  7. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013; 98: 4565-4592
  8. Alpañés M, Luque-Ramírez M, Martínez-García MÁ, Fernández-Durán E, Álvarez-Blasco F, Escobar-Morreale HF. Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome. Fertil Steril 2015; 103: 795-801
  9. Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012; 27: 3067-3073
  10. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010; 16: 347-363
  11. Daan NM, Louwers YV, Koster MP, Eijkemans MJ, de Rijke YB, Lentjes EW, Fauser BC, Laven JS. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Fertil Steril 2014; 102: 1444-1451
  12. Moran LJ, Deeks AA, Gibson-Helm ME, Teede HJ. Psychological parameters in the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod 2012; 27: 2082-2088
  13. Klimczak D, Szlendak-Saue